Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma

We aimed to develop a gene expression-based prognostic signature for isocitrate dehydrogenase (IDH) wild-type glioblastoma using clinical trial datasets representative of glioblastoma clinical trial populations.Samples were collected from newly diagnosed patients with IDH wild-type glioblastoma in t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Johnson, Radia (VerfasserIn) , Phillips, Heidi S (VerfasserIn) , Bais, Carlos (VerfasserIn) , Brennan, Cameron W (VerfasserIn) , Cloughesy, Timothy F (VerfasserIn) , Daemen, Anneleen (VerfasserIn) , Herrlinger, Ulrich (VerfasserIn) , Jenkins, Robert B (VerfasserIn) , Lai, Albert (VerfasserIn) , Mancao, Christoph (VerfasserIn) , Weller, Michael (VerfasserIn) , Wick, Wolfgang (VerfasserIn) , Bourgon, Richard (VerfasserIn) , Garcia, Josep (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 8 September 2020
In: Neuro-Oncology
Year: 2020, Jahrgang: 22, Heft: 12, Pages: 1742-1756
ISSN:1523-5866
DOI:10.1093/neuonc/noaa157
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/neuonc/noaa157
Volltext
Verfasserangaben:Radia M. Johnson, Heidi S. Phillips, Carlos Bais, Cameron W. Brennan, Timothy F. Cloughesy, Anneleen Daemen, Ulrich Herrlinger, Robert B. Jenkins, Albert Lai, Christoph Mancao, Michael Weller, Wolfgang Wick, Richard Bourgon, and Josep Garcia

MARC

LEADER 00000caa a2200000 c 4500
001 1801159769
003 DE-627
005 20220820175649.0
007 cr uuu---uuuuu
008 220507s2020 xx |||||o 00| ||eng c
024 7 |a 10.1093/neuonc/noaa157  |2 doi 
035 |a (DE-627)1801159769 
035 |a (DE-599)KXP1801159769 
035 |a (OCoLC)1341459721 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Johnson, Radia  |e VerfasserIn  |0 (DE-588)1257013505  |0 (DE-627)1801159750  |4 aut 
245 1 0 |a Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma  |c Radia M. Johnson, Heidi S. Phillips, Carlos Bais, Cameron W. Brennan, Timothy F. Cloughesy, Anneleen Daemen, Ulrich Herrlinger, Robert B. Jenkins, Albert Lai, Christoph Mancao, Michael Weller, Wolfgang Wick, Richard Bourgon, and Josep Garcia 
264 1 |c 8 September 2020 
300 |a 15 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Im Text ist "IDH" kursiv geschrieben 
500 |a Gesehen am 07.05.2022 
520 |a We aimed to develop a gene expression-based prognostic signature for isocitrate dehydrogenase (IDH) wild-type glioblastoma using clinical trial datasets representative of glioblastoma clinical trial populations.Samples were collected from newly diagnosed patients with IDH wild-type glioblastoma in the ARTE, TAMIGA, EORTC 26101 (referred to as “ATE”), AVAglio, and GLARIUS trials, or treated at UCLA. Transcriptional profiling was achieved with the NanoString gene expression platform. To identify genes prognostic for overall survival (OS), we built an elastic net penalized Cox proportional hazards regression model using the discovery ATE dataset. For validation in independent datasets (AVAglio, GLARIUS, UCLA), we combined elastic net-selected genes into a robust z-score signature (ATE score) to overcome gene expression platform differences between discovery and validation cohorts.NanoString data were available from 512 patients in the ATE dataset. Elastic net identified a prognostic signature of 9 genes (CHEK1, GPR17, IGF2BP3, MGMT, MTHFD1L, PTRH2, SOX11, S100A9, and TFRC). Translating weighted elastic net scores to the ATE score conserved the prognostic value of the genes. The ATE score was prognostic for OS in the ATE dataset (P < 0.0001), as expected, and in the validation cohorts (AVAglio, P < 0.0001; GLARIUS, P = 0.02; UCLA, P = 0.004). The ATE score remained prognostic following adjustment for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status and corticosteroid use at baseline. A positive correlation between ATE score and proneural/proliferative subtypes was observed in patients with MGMT non-methylated promoter status.The ATE score showed prognostic value and may enable clinical trial stratification for IDH wild-type glioblastoma. 
700 1 |a Phillips, Heidi S  |e VerfasserIn  |4 aut 
700 1 |a Bais, Carlos  |e VerfasserIn  |4 aut 
700 1 |a Brennan, Cameron W  |e VerfasserIn  |4 aut 
700 1 |a Cloughesy, Timothy F  |e VerfasserIn  |4 aut 
700 1 |a Daemen, Anneleen  |e VerfasserIn  |4 aut 
700 1 |a Herrlinger, Ulrich  |e VerfasserIn  |4 aut 
700 1 |a Jenkins, Robert B  |e VerfasserIn  |4 aut 
700 1 |a Lai, Albert  |e VerfasserIn  |4 aut 
700 1 |a Mancao, Christoph  |e VerfasserIn  |4 aut 
700 1 |a Weller, Michael  |e VerfasserIn  |4 aut 
700 1 |a Wick, Wolfgang  |d 1970-  |e VerfasserIn  |0 (DE-588)120297736  |0 (DE-627)080586929  |0 (DE-576)186221320  |4 aut 
700 1 |a Bourgon, Richard  |e VerfasserIn  |4 aut 
700 1 |a Garcia, Josep  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Neuro-Oncology  |d Oxford : Oxford Univ. Press, 1999  |g 22(2020), 12 vom: Dez., Seite 1742-1756  |h Online-Ressource  |w (DE-627)357167341  |w (DE-600)2094060-9  |w (DE-576)318041839  |x 1523-5866  |7 nnas  |a Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma 
773 1 8 |g volume:22  |g year:2020  |g number:12  |g month:12  |g pages:1742-1756  |g extent:15  |a Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma 
856 4 0 |u https://doi.org/10.1093/neuonc/noaa157  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20220507 
993 |a Article 
994 |a 2020 
998 |g 120297736  |a Wick, Wolfgang  |m 120297736:Wick, Wolfgang  |d 910000  |d 911100  |e 910000PW120297736  |e 911100PW120297736  |k 0/910000/  |k 1/910000/911100/  |p 12 
999 |a KXP-PPN1801159769  |e 4130110004 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"title":[{"title":"Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma","title_sort":"Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma"}],"physDesc":[{"extent":"15 S."}],"note":["Im Text ist \"IDH\" kursiv geschrieben","Gesehen am 07.05.2022"],"name":{"displayForm":["Radia M. Johnson, Heidi S. Phillips, Carlos Bais, Cameron W. Brennan, Timothy F. Cloughesy, Anneleen Daemen, Ulrich Herrlinger, Robert B. Jenkins, Albert Lai, Christoph Mancao, Michael Weller, Wolfgang Wick, Richard Bourgon, and Josep Garcia"]},"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"8 September 2020"}],"recId":"1801159769","id":{"eki":["1801159769"],"doi":["10.1093/neuonc/noaa157"]},"person":[{"given":"Radia","role":"aut","family":"Johnson","display":"Johnson, Radia"},{"given":"Heidi S","display":"Phillips, Heidi S","family":"Phillips","role":"aut"},{"given":"Carlos","role":"aut","display":"Bais, Carlos","family":"Bais"},{"display":"Brennan, Cameron W","family":"Brennan","role":"aut","given":"Cameron W"},{"given":"Timothy F","display":"Cloughesy, Timothy F","family":"Cloughesy","role":"aut"},{"given":"Anneleen","role":"aut","family":"Daemen","display":"Daemen, Anneleen"},{"family":"Herrlinger","display":"Herrlinger, Ulrich","role":"aut","given":"Ulrich"},{"given":"Robert B","role":"aut","family":"Jenkins","display":"Jenkins, Robert B"},{"given":"Albert","display":"Lai, Albert","family":"Lai","role":"aut"},{"display":"Mancao, Christoph","family":"Mancao","role":"aut","given":"Christoph"},{"display":"Weller, Michael","family":"Weller","role":"aut","given":"Michael"},{"given":"Wolfgang","display":"Wick, Wolfgang","family":"Wick","role":"aut"},{"display":"Bourgon, Richard","family":"Bourgon","role":"aut","given":"Richard"},{"display":"Garcia, Josep","family":"Garcia","role":"aut","given":"Josep"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"relHost":[{"title":[{"title_sort":"Neuro-Oncology","title":"Neuro-Oncology","subtitle":"official journal of the World Federation of Neuro-Oncology"}],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 21.07.23"],"id":{"issn":["1523-5866"],"eki":["357167341"],"zdb":["2094060-9"]},"origin":[{"dateIssuedDisp":"1999-","dateIssuedKey":"1999","publisherPlace":"Oxford ; Durham, NC","publisher":"Oxford Univ. Press ; Duke University Medical Center"}],"disp":"Development of a gene expression-based prognostic signature for IDH wild-type glioblastomaNeuro-Oncology","part":{"text":"22(2020), 12 vom: Dez., Seite 1742-1756","extent":"15","year":"2020","issue":"12","pages":"1742-1756","volume":"22"},"pubHistory":["1.1999 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"357167341"}]} 
SRT |a JOHNSONRADDEVELOPMEN8202